Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
GALT Galectin Therapeutics, Inc. daily Stock Chart
GALT [NASD]
Galectin Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.38 Insider Own7.10% Shs Outstand43.14M Perf Week19.07%
Market Cap220.88M Forward P/E- EPS next Y-0.98 Insider Trans-1.05% Shs Float33.46M Perf Month8.47%
Income-14.50M PEG- EPS next Q-0.08 Inst Own14.90% Short Float10.77% Perf Quarter8.25%
Sales- P/S- EPS this Y35.70% Inst Trans2.06% Short Ratio14.75 Perf Half Y39.13%
Book/sh0.00 P/B- EPS next Y-157.90% ROA-187.40% Target Price12.00 Perf Year29.95%
Cash/sh0.23 P/C21.87 EPS next 5Y- ROE437.50% 52W Range3.10 - 9.49 Perf YTD49.27%
Dividend- P/FCF- EPS past 5Y7.30% ROI- 52W High-46.05% Beta3.72
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low65.16% ATR0.28
Employees7 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)59.98 Volatility7.66% 5.95%
OptionableYes Debt/Eq- EPS Q/Q43.90% Profit Margin- Rel Volume2.51 Prev Close4.97
ShortableYes LT Debt/Eq- EarningsFeb 19 BMO Payout- Avg Volume244.26K Price5.12
Recom- SMA209.30% SMA5012.15% SMA2000.49% Volume613,341 Change3.02%
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
Feb-13-19 03:36PM  Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks
09:53AM  Ascendis Pharma Files IND for Hypoparathyroidism Candidate Zacks
Feb-04-19 09:27AM  Alkermes Sinks as FDA Refuses to Approve Depression Drug Zacks
Feb-01-19 10:07AM  AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA Zacks
Jan-30-19 09:30AM  Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year? Zacks
Jan-15-19 08:00AM  Galectin Therapeutics Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure GlobeNewswire
Dec-25-18 01:28PM  Did Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Sell Shares? Simply Wall St.
Dec-20-18 08:30AM  Galectin Therapeutics Announces Extension of $10 Million Line Credit GlobeNewswire -13.53%
Nov-27-18 08:15AM  New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -5.37%
Nov-19-18 09:19AM  Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit GlobeNewswire
Nov-13-18 08:00AM  Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update GlobeNewswire
Nov-05-18 08:37AM  Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks +8.09%
08:00AM  Data Collected by Exalenz Bioscience in Galectin Therapeutics Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting GlobeNewswire
Oct-15-18 10:22AM  Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference GlobeNewswire
08:00AM  Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference GlobeNewswire
Oct-11-18 07:30AM  Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-26-18 03:21PM  5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
Sep-21-18 10:43AM  Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda Zacks -5.77%
08:00AM  Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics ACCESSWIRE
Sep-20-18 08:25AM  Galectin stock lifts 15% premarket on early cancer combination trial results MarketWatch +14.55%
08:00AM  Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial GlobeNewswire
Sep-18-18 08:53AM  Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock? Zacks
Aug-31-18 02:46PM  Penny Stocks to Buy Using Technical Analysis for September 2018 Investopedia +10.41%
Aug-21-18 11:27AM  3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum ACCESSWIRE +5.39%
Aug-20-18 08:42AM  Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock? Zacks +14.99%
Aug-14-18 08:00AM  Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update GlobeNewswire
Aug-03-18 07:30AM  Market Trends Toward New Normal in Conn's, Herman Miller, TrueBlue, Brandywine Realty Trust, Tenneco, and Galectin Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jul-26-18 08:57AM  3 Stocks That Could Double Your Money Motley Fool
Jul-11-18 07:45AM  Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-27-18 12:56PM  Why Galectin Therapeutics Stock Bolted Higher Today Motley Fool +6.40%
08:00AM  Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis GlobeNewswire
Jun-26-18 08:55AM  Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock? Zacks -10.33%
Jun-22-18 10:40AM  Company Profile for Galectin Therapeutics Inc. Business Wire
Jun-17-18 04:17PM  2 Clinical-Stage Biotech Stocks That Could Soar Next Week Motley Fool
10:37AM  Market Sentiment Around Loss-Making Galectin Therapeutics Inc (NASDAQ:GALT) Simply Wall St.
Jun-16-18 07:18AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-15-18 08:07AM  3 NASH Stocks That Could Soar in the Second Half of 2018 Motley Fool +7.23%
Jun-14-18 09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Flex Pharma and Galectin Therapeutics ACCESSWIRE
Jun-12-18 08:32AM  Galectin Therapeutics Inc. Announces New CEO GlobeNewswire +5.85%
Jun-04-18 09:00AM  Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board GlobeNewswire
Jun-01-18 07:40AM  Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
May-15-18 08:00AM  Todays Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics ACCESSWIRE
May-14-18 09:05AM  Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting GlobeNewswire +19.05%
May-11-18 04:10PM  Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update GlobeNewswire
Apr-26-18 07:55AM  Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration Robotics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinsons Disease Patients with Dyskinesia ACCESSWIRE
Apr-18-18 08:00AM  Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018 GlobeNewswire
Apr-16-18 08:00AM  Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis GlobeNewswire -9.37%
Apr-05-18 08:30AM  Todays Research Reports on Trending Tickers: Exelixis and Galectin Therapeutics ACCESSWIRE
Apr-04-18 09:00AM  Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018 GlobeNewswire +15.33%
Apr-02-18 10:20AM  Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference GlobeNewswire -13.08%
Mar-29-18 06:09PM  These Biotech Stocks Have a Strong Green Close on Friday ACCESSWIRE +25.40%
08:10AM  Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-09-18 08:30AM  Galectin Therapeutics to Present at Two International Conferences in March GlobeNewswire -6.38%
Mar-08-18 08:30AM  Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference GlobeNewswire +12.04%
Mar-05-18 04:00PM  Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018 GlobeNewswire
Feb-28-18 04:35PM  Galectin Therapeutics to Present at 30th Annual ROTH Conference GlobeNewswire
Feb-16-18 08:00AM  Recent Analysis Shows SBA Communications, AMAG Pharmaceuticals, Galectin Therapeutics, Xilinx, J.B. Hunt Transport Services, and Southern Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +8.50%
Feb-06-18 09:15AM  Galectin Therapeutics to Present at BIO CEO & Investor Conference GlobeNewswire +5.08%
Jan-29-18 05:32AM  Is Galectin Therapeutics Incs (NASDAQ:GALT) CEO Pay Fair? Simply Wall St.
Jan-25-18 08:30AM  Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs GlobeNewswire -7.39%
Jan-09-18 08:20AM  Todays Research Reports on Trending Tickers: Galectin Therapeutics and Hemispherx BioPharma ACCESSWIRE -6.14%
Jan-04-18 08:40AM  Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock? Zacks
Dec-28-17 08:56AM  Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1% Zacks
Dec-20-17 02:12PM  Galectin Therapeutics Inc (GALT) Springs Up 18% as Illinois Businessman Pours Millions in Credit to Finance NASH Therapy Development SmarterAnalyst +21.76%
Dec-19-17 04:10PM  Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019 GlobeNewswire
Dec-18-17 11:01AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Galectin Therapeutics, Inc. Business Wire -14.89%
09:59AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galectin Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-14-17 09:30AM  Galectin Therapeutics Provides Corporate Update at Annual Meeting GlobeNewswire
Dec-11-17 09:00AM  Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders GlobeNewswire
Dec-06-17 08:00AM  Todays Research Reports on Stocks to Watch: Allergan plc and Galectin Therapeutics ACCESSWIRE -10.47%
Dec-05-17 02:29PM  Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure SmarterAnalyst -30.65%
10:08AM  Galectin slumps after NASH drug misses main goal of mid-stage trial Reuters
08:59AM  Galectin Therapeutics stock drops nearly 50% after negative trial results MarketWatch
08:15AM  Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial GlobeNewswire
08:15AM  Galectin says NASH drug misses main goal of midstage trial Reuters
Dec-04-17 04:00PM  Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 GlobeNewswire
Dec-01-17 08:48AM  Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks
08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Xilinx, J.B. Hunt Transport Services, Southern, FirstEnergy, AMAG Pharmaceuticals, and Galectin Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Nov-13-17 09:00AM  Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017 GlobeNewswire +7.14%
08:30AM  Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial GlobeNewswire
Nov-07-17 08:15AM  Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update GlobeNewswire +7.44%
Oct-20-17 08:30AM  Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis GlobeNewswire +6.83%
Oct-11-17 08:57AM  Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher Zacks
Sep-25-17 08:30AM  Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017 GlobeNewswire +6.81%
Sep-12-17 08:30AM  Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02 GlobeNewswire
Sep-05-17 08:30AM  Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-28-17 07:50AM  Earnings Review and Free Research Report: Zoetis Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance ACCESSWIRE
Aug-18-17 08:30AM  Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update GlobeNewswire
Aug-14-17 08:15AM  Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update GlobeNewswire +6.40%
Jul-25-17 08:30AM  Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics GlobeNewswire +6.76%
Jul-07-17 12:00PM  Galectin Therapeutics to Present at the Singular Research Summer Conference GlobeNewswire
Jun-29-17 09:02AM  Ammo, Inc. Appoints Two Senior Executives to Board of Directors GlobeNewswire
Jun-23-17 07:00AM  [$$] Drug Companies Seek to Raise Awareness of Liver Ailment The Wall Street Journal
Jun-21-17 08:30AM  Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics GlobeNewswire
Jun-13-17 08:30AM  Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial GlobeNewswire
Jun-06-17 08:30AM  Autoimmune Disease Patent Granted to Galectin Therapeutics GlobeNewswire
May-15-17 08:30AM  Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update GlobeNewswire
May-03-17 08:30AM  Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease GlobeNewswire
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FREEMAN KEVIN DDirectorFeb 08Buy4.291,5006,4281,500Feb 11 04:23 PM
LEWIS JOELDirectorFeb 07Buy4.481,0004,48465,133Feb 11 04:24 PM
LEWIS JOELDirectorJan 29Buy4.811,0004,80564,133Jan 30 05:31 PM
Uihlein Richard EDirectorJan 29Buy4.8748,500236,2442,586,789Jan 30 05:31 PM
Uihlein Richard EDirectorJan 28Buy4.773,00014,3152,538,289Jan 30 05:31 PM
AMELIO GILBERT FDirectorJan 21Option Exercise1.79103,750185,713215,935Jan 23 06:23 PM
ELDRED KARYDirectorSep 25Buy6.102,00012,20041,382Sep 26 07:59 AM
OMENN GILBERT SDirectorSep 10Sale6.008,37050,22048,191Sep 11 04:06 PM
OMENN GILBERT SDirectorSep 07Sale6.0311,00066,36556,561Sep 11 04:06 PM
Rubin MarcDirectorSep 04Option Exercise0.006,000032,481Sep 06 04:24 PM
Rubin MarcDirectorSep 04Sale6.5811,90078,25620,581Sep 06 04:24 PM
Rubin MarcDirectorAug 30Option Exercise0.0029,000084,581Sep 04 04:08 PM
Rubin MarcDirectorAug 30Sale6.0858,100353,31226,481Sep 04 04:08 PM
LEWIS JOELDirectorJun 25Buy7.061,0007,05851,480Jun 26 05:34 PM
CALLICUTT JACK WChief Financial OfficerJun 20Option Exercise4.4197,267428,94798,527Jun 21 04:18 PM
CALLICUTT JACK WChief Financial OfficerJun 20Sale8.0897,267786,0341,260Jun 21 04:18 PM
CALLICUTT JACK WChief Financial OfficerJun 19Option Exercise4.22128,733542,753129,993Jun 21 04:18 PM
CALLICUTT JACK WChief Financial OfficerJun 19Sale9.01128,7331,159,9871,260Jun 21 04:18 PM
CZIRR JAMES CDirectorJun 18Sale9.0660,000543,6002,649,786Jun 20 12:12 PM
10X Fund, L.P.10% OwnerJun 18Sale9.0660,000543,6002,649,786Jun 20 12:07 PM
10X Fund, L.P.10% OwnerJun 15Sale8.4715,475131,0732,709,786Jun 20 12:07 PM
CZIRR JAMES CDirectorJun 15Sale8.4715,475131,0732,709,786Jun 20 12:12 PM
CZIRR JAMES CDirectorJun 14Sale8.2876,385632,1332,725,261Jun 20 12:12 PM
10X Fund, L.P.10% OwnerJun 14Sale8.2876,385632,1332,725,261Jun 20 12:07 PM
TRABER PETER GPresident & CEOJun 13Option Exercise0.87100,00087,000207,333Jun 15 04:02 PM
Shlevin Harold H.Chief Operating OfficerJun 13Option Exercise0.0025,544030,918Jun 14 04:32 PM
TRABER PETER GPresident & CEOJun 13Sale7.51100,000751,000107,333Jun 15 04:02 PM
CZIRR JAMES CDirectorJun 13Sale7.17208,1401,493,2762,801,646Jun 14 07:30 PM
10X Fund, L.P.10% OwnerJun 13Sale7.17208,1401,493,2762,801,646Jun 14 07:32 PM
Shlevin Harold H.Chief Operating OfficerJun 13Sale7.7930,918240,9160Jun 14 04:32 PM
CALLICUTT JACK WChief Financial OfficerJun 12Option Exercise1.379,29412,73310,554Jun 14 04:34 PM
Shlevin Harold H.Chief Operating OfficerJun 12Sale6.5012,78083,0705,374Jun 14 04:32 PM
CALLICUTT JACK WChief Financial OfficerJun 12Sale7.019,29465,1671,260Jun 14 04:34 PM
CALLICUTT JACK WChief Financial OfficerJun 11Option Exercise1.3720,00027,40021,260Jun 12 04:48 PM
CALLICUTT JACK WChief Financial OfficerJun 11Sale6.3820,000127,5001,260Jun 12 04:48 PM
Shlevin Harold H.Chief Operating OfficerJun 11Sale6.5010,76069,94018,154Jun 12 04:50 PM
Shlevin Harold H.Chief Operating OfficerJun 08Option Exercise1.0579,29483,633184,099Jun 12 04:50 PM
TRABER PETER GPresident & CEOJun 08Option Exercise0.8770,00060,900177,333Jun 12 04:51 PM
CALLICUTT JACK WChief Financial OfficerJun 08Option Exercise0.87100,00087,000101,260Jun 12 04:48 PM
CALLICUTT JACK WChief Financial OfficerJun 08Sale5.75100,000575,0001,260Jun 12 04:48 PM
Shlevin Harold H.Chief Operating OfficerJun 08Sale5.77104,294602,04828,914Jun 12 04:50 PM
10X Fund, L.P.10% OwnerJun 08Sale5.88110,000646,8003,009,786Jun 12 06:30 PM
CZIRR JAMES CDirectorJun 08Sale5.88110,000646,8003,009,786Jun 12 06:30 PM
TRABER PETER GPresident & CEOJun 08Sale5.8670,000409,997107,333Jun 12 04:51 PM
Shlevin Harold H.Chief Operating OfficerJun 07Option Exercise1.95100,891196,801154,805Jun 08 04:33 PM
Shlevin Harold H.Chief Operating OfficerJun 07Sale5.21100,891525,26953,914Jun 08 04:33 PM
Shlevin Harold H.Chief Operating OfficerJun 06Option Exercise1.549,07813,95962,992Jun 08 04:33 PM
Shlevin Harold H.Chief Operating OfficerJun 06Sale5.159,07846,75253,914Jun 08 04:33 PM
Shlevin Harold H.Chief Operating OfficerJun 05Option Exercise1.699,92416,79769,338Jun 06 04:31 PM
Shlevin Harold H.Chief Operating OfficerJun 05Sale5.169,92451,18353,914Jun 06 04:31 PM
Shlevin Harold H.Chief Operating OfficerJun 04Option Exercise1.6010,90717,46464,821Jun 06 04:31 PM
CZIRR JAMES CDirectorJun 04Sale5.138,09341,5173,119,786Jun 05 04:58 PM
10X Fund, L.P.10% OwnerJun 04Sale5.138,09341,5173,119,786Jun 05 04:51 PM
Shlevin Harold H.Chief Operating OfficerJun 04Sale5.1510,90756,17353,914Jun 06 04:31 PM
Shlevin Harold H.Chief Operating OfficerJun 01Option Exercise1.0769,20073,979123,114Jun 04 04:51 PM
10X Fund, L.P.10% OwnerJun 01Sale5.1241,907214,5643,161,693Jun 05 04:51 PM
CZIRR JAMES CDirectorJun 01Sale5.1241,907214,5643,161,693Jun 05 04:58 PM
Shlevin Harold H.Chief Operating OfficerJun 01Sale5.1069,200352,92053,914Jun 04 04:51 PM
Shlevin Harold H.Chief Operating OfficerMay 31Option Exercise2.3250,000116,000103,914Jun 04 04:51 PM
CALLICUTT JACK WChief Financial OfficerMay 31Option Exercise0.8746,65140,58647,911Jun 04 04:56 PM
CALLICUTT JACK WChief Financial OfficerMay 31Sale5.0046,651233,2551,260Jun 04 04:56 PM
Shlevin Harold H.Chief Operating OfficerMay 31Sale5.0050,000250,00053,914Jun 04 04:51 PM
ZUCCONI THEODORE DANIELDirectorApr 16Option Exercise0.894,0003,5605,083Apr 18 04:31 PM
ZUCCONI THEODORE DANIELDirectorApr 16Sale3.584,00014,3201,083Apr 18 04:31 PM
CALLICUTT JACK WChief Financial OfficerApr 04Option Exercise0.873,3492,9144,609Apr 06 04:33 PM
CALLICUTT JACK WChief Financial OfficerApr 04Sale5.003,34916,7451,260Apr 06 04:33 PM
open in yahoo | open in reuters | open in google